Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Jacqulyne P Robichaux"'
Autor:
Jianhua Zhang, Hao Xu, Alexandre Reuben, Brian Alexander, Jack Lee, Tina Cascone, Jianjun Zhang, Kyle G Mitchell, Marcelo V Negrao, Stephen G Swisher, John V Heymach, Don L Gibbons, Jack A Roth, Ferdinandos Skoulidis, Yasir Y Elamin, Xiuning Le, Anne Tsao, Chang-Jiun Wu, Vincent A Miller, Bonnie S Glisson, Karthikeyan Murugesan, Meagan Montesion, Garrett Frampton, Katja Schulze, Ilze Bara, Vincent Shen, Sylvia Hu, Dawen Sui, Michael E Goldberg, David S Barreto, Jacqulyne P Robichaux, Carl M Gay, Lingzhi Hong, Waree Rinsurongkawong, Vassiliki Papadimitrakopoulou, Gaurav Singal, Lee A Albacker, David Shames
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Background Non-small cell lung cancer (NSCLC) patients bearing targetable oncogene alterations typically derive limited benefit from immune checkpoint blockade (ICB), which has been attributed to low tumor mutation burden (TMB) and/or PD-L1 levels. W
Externí odkaz:
https://doaj.org/article/deb634044c5641f5a4d7746a8b39b598
Autor:
Victoria M. Raymond, Junqin He, John V. Heymach, Xiaoshan Zhang, Jing Wang, Lemei Hu, Hai T. Tran, Alexa B. Schrock, Ferdinandos Skoulidis, Jhanelle E. Gray, Bingliang Fang, Monique B. Nilsson, Jianjun Zhang, Susan Varghese, Simon Heeke, Waree Rinsurongkawong, J. Kevin Hicks, Jennifer Saam, Yasir Elamin, R. S. K. Vijayan, Hibiki Udagawa, Heather Lin, Russell Madison, Min Jin Ha, Lixia Diao, Lingzhi Hong, Xiuning Le, Alissa Poteete, Chenghui Ren, Fahao Zhang, Cross Jason, Jacqulyne P. Robichaux, Xiaoke Liu
Publikováno v:
Nature. 597:732-737
Epidermal growth factor receptor (EGFR) mutations typically occur in exons 18–21 and are established driver mutations in non-small cell lung cancer (NSCLC)1–3. Targeted therapies are approved for patients with ‘classical’ mutations and a smal
Autor:
Lixia Diao, Esra A. Akbay, Linghua Wang, Won-Chul Lee, Kwok-Kin Wong, Don L. Gibbons, Luisa M. Solis Soto, Ruiping Wang, Stephen G. Swisher, Jing Wang, Runzhe Chen, Roohussaba Khairullah, You Hong Fan, Alexandre Reuben, Mingrui Zhu, Jack A. Roth, Boris Sepesi, Irene Guijarro Munoz, John V. Heymach, Carmen Behrens, Jianhua Zhang, Jacqulyne P. Robichaux, Marcelo V. Negrao, Humam Kadara, Edwin R. Parra, Monique B. Nilsson, Lorenzo Federico, Tatiana Karpinets, Ignacio I. Wistuba, Chantale Bernatchez, Jianjun Zhang, Daniel J. McGrail, S. Patel, Xiuning Le, Ara A. Vaporciyan, Yasir Elamin, Cara Haymaker, Jun Li, Lauren Averett Byers
Publikováno v:
Journal of Thoracic Oncology. 16:583-600
Introduction Lung adenocarcinomas harboring EGFR mutations do not respond to immune checkpoint blockade therapy and their EGFR wildtype counterpart. The mechanisms underlying this lack of clinical response have been investigated but remain incomplete
CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance
Autor:
Monique B. Nilsson, Yan Yang, Simon Heeke, Sonia A. Patel, Alissa Poteete, Hibiki Udagawa, Yasir Y. Elamin, Cesar A. Moran, Yukie Kashima, Thiruvengadam Arumugam, Xiaoxing Yu, Xiaoyang Ren, Lixia Diao, Li Shen, Qi Wang, Minying Zhang, Jacqulyne P. Robichaux, Chunhua Shi, Allyson N. Pfeil, Hai Tran, Don L. Gibbons, Jason Bock, Jing Wang, John D. Minna, Susumu S. Kobayashi, Xiuning Le, John V. Heymach
Publikováno v:
Cancer Cell. 41:340-355.e6
Autor:
Lei Feng, Jacqulyne P. Robichaux, Yasir Elamin, Jianjun Zhang, Brett W. Carter, Don L. Gibbons, George R. Blumenschein, John V. Heymach, Frank E. Mott, Mehmet Altan, Marcelo V. Negrao, Vincent K. Lam, Frank V. Fossella, Anisha B. Patel, Anne S. Tsao, Xiuning Le
Publikováno v:
J Clin Oncol
PURPOSE Targeted therapies against non–small-cell lung cancer (NSCLC) harboring HER2 mutations remain an unmet need. In this study, we assessed the efficacy and safety of poziotinib in patients with HER2 exon 20 mutant advanced NSCLC in a single-ar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce847f3cddbf0739c9448e42355323c1
https://europepmc.org/articles/PMC8887948/
https://europepmc.org/articles/PMC8887948/
Publikováno v:
Cancer cell. 39(9)
The randomized ARTEMIS study demonstrates that adding the VEGF inhibitor bevacizumab to the EGFR inhibitor erlotinib improves progression-free survival in EGFR mutant non-small-cell lung cancer by more than 6 months, with even greater benefits seen i
Autor:
Marcelo V Negrao, Ferdinandos Skoulidis, Meagan Montesion, Katja Schulze, Ilze Bara, Vincent Shen, Hao Xu, Sylvia Hu, Dawen Sui, Yasir Y Elamin, Xiuning Le, Michael E Goldberg, Karthikeyan Murugesan, Chang-Jiun Wu, Jianhua Zhang, David S Barreto, Jacqulyne P Robichaux, Alexandre Reuben, Tina Cascone, Carl M Gay, Kyle G Mitchell, Lingzhi Hong, Waree Rinsurongkawong, Jack A Roth, Stephen G Swisher, Jack Lee, Anne Tsao, Vassiliki Papadimitrakopoulou, Don L Gibbons, Bonnie S Glisson, Gaurav Singal, Vincent A Miller, Brian Alexander, Garrett Frampton, Lee A Albacker, David Shames, Jianjun Zhang, John V Heymach
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundNon-small cell lung cancer (NSCLC) patients bearing targetable oncogene alterations typically derive limited benefit from immune checkpoint blockade (ICB), which has been attributed to low tumor mutation burden (TMB) and/or PD-L1 levels. We
Autor:
Jacqulyne P, Robichaux, Xiuning, Le, R S K, Vijayan, J Kevin, Hicks, Simon, Heeke, Yasir Y, Elamin, Heather Y, Lin, Hibiki, Udagawa, Ferdinandos, Skoulidis, Hai, Tran, Susan, Varghese, Junqin, He, Fahao, Zhang, Monique B, Nilsson, Lemei, Hu, Alissa, Poteete, Waree, Rinsurongkawong, Xiaoshan, Zhang, Chenghui, Ren, Xiaoke, Liu, Lingzhi, Hong, Jianjun, Zhang, Lixia, Diao, Russell, Madison, Alexa B, Schrock, Jennifer, Saam, Victoria, Raymond, Bingliang, Fang, Jing, Wang, Min Jin, Ha, Jason B, Cross, Jhanelle E, Gray, John V, Heymach
Publikováno v:
Nature. 597(7878)
Epidermal growth factor receptor (EGFR) mutations typically occur in exons 18-21 and are established driver mutations in non-small cell lung cancer (NSCLC)
Autor:
Waree Rinsurogkawong, John V. Heymach, Emily Roarty, Daniel R. Gomez, Lara Lacerda, Jianjun Zhang, Jadi M. Bohac, Jacqulyne P. Robichaux, Stephen G. Swisher, Vassiliki A. Papadimitrakopoulou, Melissa K. Shorter, Jack A. Roth, Jeff Lewis, Mara B. Antonoff, Hai T. Tran, Marcelo V. Negrao, Yasir Elamin, Xiuning Le
Publikováno v:
Clinical Lung Cancer. 20:43-47
Introduction Although most NSCLC patients with sensitizing epidermal growth factor receptor (EGFR) mutations have an impressive initial response, the vast majority has residual disease and develops acquired resistance after 9 to 14 months of EGFR tyr
Autor:
Hibiki Udagawa, Jacqulyne P. Robichaux, Yasir Y. Elamin, Junqin He, Monique B. Nilsson, John V. Heymach
Publikováno v:
Cancer Research. 82:1182-1182
NRG1 gene fusions are rare clinically actionable somatic alterations identified in 0.1% - 0.2% of all tumors. Currently, there are no approved targeted therapies for patients with NRG1 fusion-positive cancer. Previous studies have demonstrated that N